Back to results
US 2017/0246139 A1Published application
Synergistic compositions for treating microbial infections
AssigneesUniversity of Rochester, Temple University of the Commonwealth System of Higher Education
InventorsPaul M. Dunman, Wayne Childers
Life of this patent
Estimating the term…
Abstract
Synergistic pharmaceutical compositions including an RNase P inhibitor and a tRNA synthetase inhibitor are provided, as well as methods for their use in treating infections. Also provided herein are methods of using the compositions to inhibit a bacterial tRNA synthetase in a cell and to decolonize bacteria on a surface.
Claims32
A pharmaceutical composition, comprising:
- an RNase P inhibitor of the following formula:
- or a pharmaceutically acceptable salt or prodrug thereof, wherein:
- L1 and L2 are each independently a direct bond or a divalent moiety selected from the group consisting of -substituted or unsubstituted alkyl-, -substituted or unsubstituted heteroalkyl-, -substituted or unsubstituted alkenyl-, -substituted or unsubstituted amino-, -substituted or unsubstituted amido-, and -substituted or unsubstituted alkoxy-;
- R1 and R2 are each independently selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
- and
- X1 and X2 are each independently O or S;
- and
- a tRNA synthetase inhibitor.
5 more elements
A pharmaceutical composition, comprising:
- an RNase P inhibitor of the following formula:
- or a pharmaceutically acceptable salt or prodrug thereof, wherein
- L1 and L2 are each independently selected from the group consisting of substituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl;
- R1 and R2 are each independently selected from the group consisting of substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
- and
- X1 and X2 are each independently O or S;
- and
- a tRNA synthetase inhibitor.
5 more elements
A pharmaceutical composition, comprising:
- an RNase P inhibitor of the following structure:
- and
- mupirocin.
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.